The trademark application TYCRUVA was filed by Bristol-Myers Squibb Company, a U.S. corporation (the "Applicant"). The application was published for oppositions on June 6, 2021, and it was registered by office on September 13, 2021 without any oppositions.
The application was filed in English (French was selected as the second language).